Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

With the threat of Trump administration's tariffs swirling and biopharma companies bracing for impact, many are announcing ...

Like several other biopharmas before it, UCB has turned to perhaps the most recognizable dermatologist in the U.S. to add ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Pharmacy benefit managers (PBMs) are up to bat in the perpetual blame game between PBMs and the pharmaceutical industry. | ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...